Ra Pharmaceuticals, Inc. (RARX)


Stock Price Forecast

April 1, 2020


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Ra Pharmaceuticals, Inc. chart...

About the Company

Ra Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of peptide-based drugs. It uses Extreme Diversity platform that allows to produce synthetic macrocyclic peptides. The company was founded by James W. Broderick and Douglas A. Treco on June 27, 2008 and is headquartered in Cambridge, MA.

Sector

Health Technology

Industry

Pharmaceuticals: Major

Employees

89

CEO

Douglas A. Treco

Exchange

NASDAQ

Website

http://www.rapharma.com

$3M

Total Revenue

89

Employees

$2B

Market Capitalization

-20.78

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $RARX News

AstraZeneca to Buy Fusion Pharmaceuticals for Up to $2.4B as Firm Expands Cancer Pipeline

on MSN ago, source:

AstraZeneca said on Tuesday it will acquire biotech company Fusion Pharmaceuticals for up to $2.4 billion, expanding its ...

Biotech Stock Soars on AstraZeneca Buyout

9d ago, source: SchaeffersResearch.com

Fusion Pharmaceuticals (FUSN) is soaring after news that AstraZeneca will acquire the company for $2.4 billion ...

AstraZeneca Buys US Biopharma Firm Fusion

10d ago, source:

Anglo-Swedish pharmaceuticals giant AstraZeneca agreed Tuesday to buy US biopharma firm Fusion for up to $2.4 billion, its latest expansion into cancer treatments.

Astrazeneca’s $2.4B Fusion buyout boosts radiopharma field

9d ago, source: BioWorld

Validating Fusion Pharmaceuticals Inc.’s radiopharmaceutical technology and manufacturing capabilities, Astrazeneca plc offered to buy the firm for $2 billion up front in cash, plus a contingent value ...

AstraZeneca's $2.4B Fusion Pharmaceuticals' Acquisition Signals Shift In Efforts From Traditional Regimens For More Targeted Cancer Treatments

10d ago, source: Benzinga on MSN

Tuesday, AstraZeneca Plc (NASDAQ:AZN) agreed to acquire Fusion Pharmaceuticals Inc (NASDAQ:FUSN) for $21.00 per share in cash ...

Astra to Buy Fusion Pharma in Hunt for New Cancer Treatments

on MSN ago, source:

AstraZeneca Plc agreed to buy Fusion Pharmaceuticals Inc. for as much as $2.4 billion as it seeks to transform cancer ...

AstraZeneca To Buy Fusion Pharma For Up To $2.4 Bln

10d ago, source:

(RTTNews) - British drug major AstraZeneca Plc. (AZN.L, AZN) announced Tuesday that it has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc. (FUSN) in about $2.4 billion deal.

AstraZeneca bets on next-generation cancer therapy with $2 billion Fusion deal

on MSN ago, source:

AstraZeneca said on Tuesday it will buy Canadian drug developer Fusion Pharmaceuticals Inc for $2 billion in cash as the ...

Fusion Pharmaceuticals to be Acquired by AstraZeneca, Accelerating Development of Next-Generation Radioconjugates to Treat Cancer

10d ago, source:

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation ...

AstraZeneca to buy Ontario cancer treatment developer Fusion Pharmaceuticals

on MSN ago, source:

Fusion, based in Hamilton, is focused on developing radioconjugates which are used to deliver radiation directly to cancer ...

Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Granted Priority Review by China’s NMPA

2d ago, source:

The Center for Drug Evaluation (CDE) of the Chinese drug authority NMPA accepted the filing and granted priority review for vamorolone in DMD for patients aged 4 years and older which could, subject ...

AstraZeneca buys Hamilton-based smart cancer drug maker Fusion Pharmaceuticals for $2-billion

10d ago, source:

Deal will be ‘good for Canada’ as buyer will keep and expand local manufacturing presence, former Fusion chairman says ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...